Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda J Hooper

Showing results (21-30 of 125) with videos related to

Pageof 13
Sort By:
Pathology|January 1, 2019
Lipids and cardiovascular diseaseJohn R Burnett, Amanda J Hooper, Robert A Hegele
Expert Opinion on Pharmacotherapy|December 8, 2015
Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?Michael M Page, Amanda J Hooper, John R Burnett
Expert Opinion on Pharmacotherapy|November 30, 2024
Response to the letter to the editor: 'Olezarsen, a liver-directed <i>APOC3</i> ASO therapy for hypertriglyceridemia'Amanda J Hooper, Damon A Bell, John R Burnett
Expert Opinion on Pharmacotherapy|August 8, 2025
Lomitapide for the treatment of pediatric homozygous familial hypercholesterolemiaAmanda J Hooper, Damon A Bell, John R Burnett
Expert Opinion on Investigational Drugs|November 29, 2025
Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a)Xuan L Tang, Amanda J Hooper, John R Burnett
Circulation Research|January 2, 2015
Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer proteinAmanda J Hooper, John R Burnett, Gerald F Watts
Current Opinion in Lipidology|February 6, 2020
Tangier disease: update for 2020Amanda J Hooper, Robert A Hegele, John R Burnett
Journal of the American College of Cardiology|December 4, 2020
Remnant Cholesterol and Atherosclerotic Cardiovascular Disease RiskJohn R Burnett, Amanda J Hooper, Robert A Hegele
Expert Opinion on Investigational Drugs|October 5, 2024
Assessing the clinical potential of plozasiran, an <i>APOC3</i> siRNA therapy for severe hypertriglyceridemiaXuan L Tang, Amanda J Hooper, John R Burnett
Critical Reviews in Clinical Laboratory Sciences|January 5, 2012
Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statinsFathimath Faiz, Amanda J Hooper, Frank M van Bockxmeer
Pageof 13

Showing results (21-30 of 125) with videos related to

Sort By:
Pageof 13
Pathology|January 1, 2019
Lipids and cardiovascular diseaseJohn R Burnett, Amanda J Hooper, Robert A Hegele
Expert Opinion on Pharmacotherapy|December 8, 2015
Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?Michael M Page, Amanda J Hooper, John R Burnett
Expert Opinion on Pharmacotherapy|November 30, 2024
Response to the letter to the editor: 'Olezarsen, a liver-directed <i>APOC3</i> ASO therapy for hypertriglyceridemia'Amanda J Hooper, Damon A Bell, John R Burnett
Expert Opinion on Pharmacotherapy|August 8, 2025
Lomitapide for the treatment of pediatric homozygous familial hypercholesterolemiaAmanda J Hooper, Damon A Bell, John R Burnett
Expert Opinion on Investigational Drugs|November 29, 2025
Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a)Xuan L Tang, Amanda J Hooper, John R Burnett
Circulation Research|January 2, 2015
Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer proteinAmanda J Hooper, John R Burnett, Gerald F Watts
Current Opinion in Lipidology|February 6, 2020
Tangier disease: update for 2020Amanda J Hooper, Robert A Hegele, John R Burnett
Journal of the American College of Cardiology|December 4, 2020
Remnant Cholesterol and Atherosclerotic Cardiovascular Disease RiskJohn R Burnett, Amanda J Hooper, Robert A Hegele
Expert Opinion on Investigational Drugs|October 5, 2024
Assessing the clinical potential of plozasiran, an <i>APOC3</i> siRNA therapy for severe hypertriglyceridemiaXuan L Tang, Amanda J Hooper, John R Burnett
Critical Reviews in Clinical Laboratory Sciences|January 5, 2012
Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statinsFathimath Faiz, Amanda J Hooper, Frank M van Bockxmeer
Pageof 13